USC Scientists Find New Way to Fight Alzheimer's

Scientists at USC have identified promising drug candidates that might help millions at risk for Alzheimer's disease by targeting a newly understood source of brain inflammation.

The research team focused on an enzyme called cPLA2, which appears to fuel harmful inflammation in the brain. By studying people with the APOE4 gene (the strongest genetic risk factor for Alzheimer's), they discovered that higher enzyme activity increased disease likelihood.

The challenge was tricky. The enzyme also supports healthy brain function, so completely blocking it would cause problems. Plus, any potential drug needed to be small enough to cross the blood brain barrier and actually reach where it was needed.

Dr. Hussein Yassine, who directs the Center for Personalized Brain Health at USC's Keck School of Medicine, led the team in finding a solution. They used powerful computers to screen billions of possible molecules, looking for compounds that could selectively reduce the harmful activity while leaving normal brain functions alone.

One compound emerged as the frontrunner. In tests using human brain cells under Alzheimer's stress conditions, it successfully reduced the harmful enzyme activation. When tested in mice, the compound crossed into the brain and influenced the inflammatory pathways linked to the disease.

The findings, published in the journal npj Drug Discovery, represent years of collaboration across multiple USC departments. Pharmacologists prepared the compounds for testing. Computer scientists developed the screening methods. Neuroscientists verified the results in living systems.

The Bright Side

This discovery matters beyond just one potential treatment. The research shows that personalized medicine for Alzheimer's is becoming more realistic. People with the APOE4 gene could potentially take preventive action before symptoms appear, rather than waiting until memory loss begins.

The team is now moving toward human trials, carefully testing whether the approach is safe and effective. While they're cautious about making promises, the early results suggest that targeting inflammation could meaningfully reduce Alzheimer's risk for vulnerable populations.

For the 25% of Americans who carry at least one APOE4 gene, this research offers something precious: a path forward where none existed before.